Drug Investigation

, Volume 4, Issue 4, pp 283–291 | Cite as

New Data on the Safety of Loratadine

  • Paul B. Van Cauwenberge
Original Research Article

Summary

Since the European registration of loratadine, a significant amount of new and previously unpublished data have become available supporting the generally good tolerability profile of this nonsedating antihistamine. This report describes safety data obtained from more than 55 000 additional patients in open and controlled studies, and also describes information obtained from postmarketing surveillance data during the widespread use of this agent. These new data demonstrate that loratadine does not possess any significant CNS or anticholinergic effects and the side effects are comparable with those associated with placebo. Loratadine is apparently lacking in any unusual or serious effects and is well tolerated by a wide spectrum of patient populations, including the elderly and patients taking a variety of concomitant medications for concurrent illnesses.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bradley CM, Nicholson AN. Studies on the central effects of the H1-antagonist, loratadine. European Journal of Clinical Pharmacology 32: 419–421, 1987PubMedCrossRefGoogle Scholar
  2. Clissold SP, Sorkin EM, Goa KL. Loratadine: a preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 37: 42–57, 1989PubMedCrossRefGoogle Scholar
  3. Friedman HM. Loratadine: a potent, nonsedating, and long-acting H1 antagonist. American Journal of Rhinology 1: 95–99, 1987CrossRefGoogle Scholar
  4. Gaillard AWK, Gruisen A, de Jong R. The influence of antihistamines on human performance. European Journal of Clinical Pharmacology 35: 1–5, 1988CrossRefGoogle Scholar
  5. Herberg KW. Studie zur Fahrtuchtigkeit nach einnahme von Loratadin. Munchener Medizinische Wochenschrift 132: 463–467, 1990Google Scholar
  6. Hilbert R, Radwanski E, Weglein R, Luc V, Perentesis G, et al. The pharmacokinetics of loratadine in normal geriatric volunteers. Journal of International Medical Research 16: 50–60, 1988PubMedGoogle Scholar
  7. Mann KV, Crowe JP, Tietze KJ. Nonsedating histamine H1-receptor antagonists. Clinical Pharmacy 8: 331–344, 1989PubMedGoogle Scholar
  8. Meltzer EO. Evaluation of clemastine and a new antihistamine (loratadine) in patients with seasonal allergic rhinitis. 44th Annual Congress, American College of Allergists, Boston, November, 1987Google Scholar
  9. Moser L, Plum H, Buckmann M. Lack of potentiation of the effect of alcohol by loratadine. 13th Congress of the European Academy of Allergology and Clinical Immunology, Budapest, May, 1986Google Scholar
  10. Roth T, Roehrs T, Koshorek G, Sicklesteel J, Zorick F. Sedative effects of antihistamines. Journal of Allergy and Clinical Immunology 80: 94–98, 1987PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Paul B. Van Cauwenberge
    • 1
  1. 1.Universitair Ziekenhuis, Kliniek voor Neus-Keel-Oor-ZiektenGentBelgium

Personalised recommendations